维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

15篇 您的检索式：作者名="Chlabicz"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	The substances of plant origin that inhibit protein biosynthesis显示文摘	Galasinski W Chlabicz J Paszkiewcz-Gadek A	1996	Acta Pol Pharm1996，53，5：	1
	2	The substances of plant origin that inhibit protein biosynthesis显示文摘	GALASINSKI W CHLABICZ J PASZKIEWICZ-GADEK A	1996	Acta Pol Pharm1996，53，5：	1
	3	Changing HCV genotypes distribution in Poland -relation to source and time of infection显示文摘	Chlabicz S Flisiak R Kowalczuk O	2008	J Clin Virol2008，42，2：	1
	4	Changing HCV genotypes distribution in Poland -relation to source and time of infection显示文摘	Chlabicz S Flisiak R Kowalczuk O	2008	J Clin Virol2008，42，2：	1
	5	The substances of plant origin that inhibit protein biosynthesis显示文摘	Galasinski W Chlabicz J Paszkiewicz-Gadek A	1996	Acta Pol Pharm1996，53，5：	1
	6	The substances of plant origin that inhibit protein biosynthesis 显示文摘	Galasinski W Chlabicz J Paszkiewcz-Gadek A	1996	Acta Pol Pharm1996，53，5：	1
	7	The substances of plant origin that inhibit protein biosynthesis 显示文摘	Galasinski W Chlabicz J Paszkiewcz-Gadek A	1996	Acta Pol Pharm1996，53，5：	1
	8	Epidemiological features of patients infected with HCV genotype 4 in Poland:Epidemiology of HCV genotype 4 in Poland显示文摘	Chlabicz S Flisiak R Lapinski TW	2011	Hepat Mon2011，11，3：	1
	9	Serum hyaluronanas a possible biomarker of liver insufficiency in cirrhoticpatients显示文摘	Grzeszczuk A Chlabicz S Panasiuk A	2002	Rocz Akad Med Bialymst2002，47，1：	1
	10	Changing HCV genotypes distribution in Poland—Relation to source and time of infection显示文摘	Slawomir Chlabicz Robert Flisiak Oksana Kowalczuk Anna Grzeszczuk Barbara Pytel-Krolczuk Danuta Prokopowicz Lech Chyczewski	2008	Journal of Clinical Virology2008，，2：	1
	11	Serum hyaluronan as a possible biomarker of liver insufficiency in cirrhotic patients显示文摘	Grzeszczuk A Chlabicz S Panasiuk A	2002	Rocz Akad Med Bialymst2002，47，：	1
	12	The substances of plant origin that inhibit protein biosynthesis显示文摘	Galasinski W Chlabicz J Paszkiewicz-Gadek A		0，，05：	1
	13	The substances of plant origin that inhibit protein biosynthesis 显示文摘	Galasinski W Chlabicz J Paszkiewcz-Gadek A	1996	Acta Pol Pharm1996，53，5：	1
	14	Four-year follow up of hepatitis C patients vaccinated against hepatitis B virus显示文摘AIM: Patients with chronic hepatitis C have been recommended to receive vaccinations against hepatitis B. Our study aimed at evaluating the hepatitis B immunogenicity and efficacy against hepatitis B virus infection 4 years after primary immunization series in a group of patients with chronic hepatitis C.METHODS: We recruited 36 out of 48 hepatitis C virus (HCV) infected individuals who were vaccinated against hepatitis B virus (20 μg of recombinant HBsAg at 0-1-6mo schedule) in 1998. Here we measured anti-HBs titers and anti-HBc 4 years after delivery of the third dose of primary immunization series.RESULTS: After 4 years a total of 13/36 (36%) HCV infected patients had seroprotective titers of anti-HBs compared with 9/10 (90%) in the control group, (P<0.05).Similarly the mean concentration of anti-HBs found in hepatitis C patients was significantly lower than that found in healthy subjects (18.3 and 156.0 mIU/mL respectively (P<0.05). None of the HCV infected patients or controls became infected with HBV during the study period as confirmed by anti-HBc negativity.CONCLUSION: We demonstrated that 4 years after HBV immunizations' more than 60% of vaccinated HCV patients did not maintain seroprotective levels of anti-HBs, which might put them at risk of clinically significant breakthrough infections. Further follow-up studies are required to clarify whether memory B and T lymphocytes can provideprotection in chronic hepatitis C patients in the absence or inadequate titers of anti-HBs.	Slawomir Chlabicz Tadeusz Wojciech Lapinski Anna Grzeszczuk Danuta Prokopowicz	2005	World Journal of Gastroenterology2005，11，12：	0
	15	Known and probable risk factors for hepatitis C infection:A case series in north-eastern Poland显示文摘瞄准: 与丙肝在医院里描述病人的风险侧面在波兰的病毒(HCV ) 感染。方法:用一张结构化的问询表,有证实的 HCV 感染的所有病人关于风险因素被会见。结果:在学习的 250 个病人之中,在 1993 前的输送是在 26% 的主要风险因素,在 9% 的静脉内的药使用背景和在在 9% 的保健的职业暴露。女人们是更可能的在 1993 前并且不太多半有职业暴露或输送的历史经历次要的外科。已知的医院的风险因素(在 1993 前的输送,分离) 为 27% 感染负责,可能的医院的因素(在 1992 以后的输送,次要的外科) 为 14% 并且进一步, 9% 是职业结盟获得的感染。结论:小心的历史调查能识别一知道或为在有 HCV 感染的 59% 病人的 HCV 获得的可能的风险因素。在波兰的预防活动应该在保健设定集中于感染控制措施。	Slawomir Chlabicz Robert Flisiak Anna Grzeszczuk Oksana Kovalchuk Danuta Prokopowicz Lech Chyczewski	2006	World Journal of Gastroenterology2006，12，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费